1·Results Between-group differences in glycated hemoglobin levels were lost after the first year.
结果：组间糖化血红蛋白差异在随后的第一年就不存在了。
2·The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.
另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。
3·Levels of blood glucose, glycated serum protein, insulin and lipid profile were determined.
测定血糖、糖化血清蛋白、血脂和胰岛素水平。
4·The primary end point was the change from the baseline glycated hemoglobin level.
主要终点是糖化血红蛋白水平较基线时的变化。
5·Within the past decade, several new drugs that result in "glycemic durability" - a reduction in the glycated hemoglobin level - have been approved by the FDA.
在过去的10年中，FDA批准了不少注重于持续降糖的新药物，其主要的指标是糖化血红蛋白。